Table 2:

Baseline characteristics by evidence of use of OACs among privately insured members with atrial fibrillation and CHA₂DS₂-VASC scores ≥2

		Patients Not Using an OAC at Baseline*		Patients Using an OAC at Baseline*		P-value
Totals		43,826		76,696
		N	%	N	%
Age						<0.0001
<30–44		150	0.3	158	0.2
45–64		3,375	7.7	6,407	8.4
65–74		13,343	30.4	24,059	31.4
75–80+		26,958	61.5	46,072	60.1
Female sex		21,171	48	35,244	46	<0.0001
Geographic Region						<0.0001
New England		1,245	3	3,602	5
Mid-Atlantic		1,879	4	4,374	6
South-Atlantic		23,488	54	42,155	55
Midwest		12,204	28	17,190	22
Mountain		2,074	5	3,725	5
Pacific		2,921	7	5,635	7
Unknown		15	0	15	0
Anemia		22,702	52	36,565	48	<0.0001
Hypertension		41,247	94	73,342	96	<0.0001
Diabetes		17,172	39	33,325	44	<0.0001
Peripheral vascular disease		13,253	30	22,971	30	0.29
Prior cerebrovascular or thromboembolic event		14,127	32	23,472	31	<0.0001
Prior cerebrovascular event		9,075	21	18,214	24	<0.0001
Stroke or TIA		7,493	17	15,149	20	<0.0001
TIA		5,850	13	11,603	15	<0.0001
Stroke		3,547	8	7,969	10	<0.0001
Heart failure		17,694	40	36,468	48	<0.0001
Kidney disease		3,328	8	5,193	7	<0.0001
Dialysis		1,498	3	2,398	3	0.006
History of MI		5,405	12	8,170	11	<0.0001
History of CABG		6,529	15	10,639	14	<0.0001
CHA2DS2-VASC						<0.0001
0–1		0	0	0	0
2		5,264	12	6,940	9
3		8,240	19	13,775	18
4		10,179	23	18,126	24
5		8,620	20	16,158	21
6		5,798	13	11,022	14
7		3,374	8	6,441	8
8		1,809	4	3,342	4
9		542	1	892	1
Mean		5	NA	5	NA	>0.99
SD		1.7	NA	1.6	NA
Atria score						<0.0001
<= 3 (low)		20,852	48	39,238	51
4 (intermediate)		6,021	14	10,860	14
5 (high)		16,953	39	26,598	35
Hospitalizations in the prior 6 months						0.15
0		37,382	85	65,791	86
1		5,007	11	8,476	11
2		1,032	2.4	1,743	2.3
≥3		405	0.9	686	0.9

^*OAC use at baseline was defined as any OAC use in the prior 12 months.